Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme

• US 20130022592A1
• Filed: 06/15/2012
• Published: 01/24/2013
• Est. Priority Date: 06/17/2011
• Status: Abandoned Application

• Current Assignee: Halozyme, Inc. (Halozyme Therapeutics, Inc.)
• Original Assignee: Halozyme, Inc. (Halozyme Therapeutics, Inc.)
• Inventors: Vaughn, Daniel Edward, Frost, Gregory I., Muchmore, Douglas Boyer
• Application Number:
  US13/507,261
• Publication Number:
  US 20130022592A1
• Time in Patent Office: Days
• US Class Current: 424/94.62
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 7/12 Antidiuretics, e.g. drugs for diabetes insipidus ADH A61P5/10

Abstract

Provided are methods for continuous subcutaneous insulin infusion (CSII) that employ a hyaluronan-degrading enzyme, including a recombinant human PH20 (rHuPH20). The methods can be used to more consistently control blood glucose during the course of CSII. The methods can be used to treat subjects having diabetes or other insulin-associated disease or condition.

Claims

1. A method of controlling blood glucose in a subject by continuous subcutaneous insulin infusion (CSII) therapy, comprising:

a) administering a composition comprising a hyaluronan-degrading enzyme to the subject; and

then

b) continuously infusing a fast-acting insulin by CSII to the subject, wherein the difference in insulin absorption is minimized or reduced over the course of infusion set life compared to CSII performed in the absence of the hyaluronan-degrading enzyme.

2. The method of claim 1, wherein:

the hyaluronan-degrading enzyme is in an amount that effects an ultra-fast insulin response at the outset of infusion set life in the subject;

or

the hyaluronan-degrading enzyme is in an amount sufficient to catalyze the hydrolysis of hyaluronic acid to increase tissue permeability.

3. The method of claim 1, wherein in step b) the continuous infusion is effected by a continuous infusion device that comprises an insulin pump, a reservoir containing the fast-acting insulin, an optional glucose monitor, and an infusion set for subcutaneous infusion of the composition.

4. The method of claim 3, wherein the continuous infusion device comprises an insulin pump, a reservoir containing the fast-acting insulin, a glucose monitor, and an infusion set for subcutaneous infusion of the composition.

5. The method of claim 1, wherein the continuous infusion device provides an open-loop or closed-loop system.

6. The method of claim 1, wherein:

the step b) of continuously infusing a fast-acting insulin by CSII continues for a predetermined interval; and

at the end of each interval steps a) and b) are repeated.

7. The method of claim 6, wherein after the end of each interval the infusion set is replaced.

8. The method of claim 6, wherein each predetermined interval is more than a day or is several days.

9. The method of claim 8, wherein several days is 2 days to 4 days.

10. The method of claim 1, wherein in step a) the hyaluronan-degrading enzyme is administered at or near the site of infusion of the composition in step b).

11. The method of claim 1, wherein the hyaluronan-degrading enzyme in step a) and the fast-acting insulin composition in step b) are administered through the same injection site.

12. The method of claim 1, wherein the hyaluronan-degrading enzyme in step a) and the fast-acting insulin composition in step b) are administered through different injection sites.

13. The method of claim 1, wherein the hyaluronan-degrading enzyme is administered 1 minute to 12 hours, 5 minutes to 6 hours, 30 minutes to 3 hours, 1 hour to 2 hours, 15 seconds to 1 hour, 30 seconds to 30 minutes or 1 minute to 15 minutes prior to infusion of the fast-acting insulin.

14. The method of claim 1, wherein the hyaluronan-degrading enzyme in step a) is administered no more than 2 hours before infusion of the fast-acting insulin.

15. The method of claim 1, wherein the hyaluronan-degrading enzyme is a hyaluronidase.

16. The method of claim 1, wherein the hyaluronan-degrading enzyme is a hyaluronidase that is active at neutral pH.

17. The method of claim 1, wherein:

the hyaluronan-degrading enzyme lacks a glycosylphosphatidylinositol (GPI) anchor or is not membrane-associated when expressed from a cell;

or

the hyaluronan-degrading enzyme contains C-terminal truncations of one or more amino acid residues to remove all or part of a GPI anchor.

18. The method of claim 1, wherein the hyaluronan-degrading enzyme is a hyaluronidase that is a PH20 or a C-terminally truncated fragment thereof.

19. The method of claim 1, wherein the hyaluronan-degrading enzyme is a PH20 polypeptide that has the sequence of amino acids set forth in any of SEQ ID NOS:

4-9, 47-48, 234-254, and 267-273, or a sequence of amino acids that exhibits at least 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOS;

4-9, 47-48, 234-254, and 267-273.

20. The method of claim 1, wherein the hyaluronan-degrading enzyme is a C-terminal truncated PH20 that comprises a sequence of amino acids set forth in any of SEQ ID NOS:

4-9.

21. The method of claim 1, wherein:

the hyaluronan-degrading enzyme in step a) is administered in an amount that is functionally equivalent to between or about between 1 Unit to 200 Units, 5 Units to 150 Units, 10 Units to 150 Units, 50 Units to 150 Units or 1 Unit to 50 Units;

or

the hyaluronan-degrading enzyme in step a) is administered in an amount that is between or about between 8 ng to 2 μ

g, 20 ng to 1.6 μ

g, 80 ng to 1.25 μ

g or 200 ng to 1 μ

g.

22. The method of claim 1, wherein the fast-acting insulin is a regular insulin.

23. The method of claim 22, wherein the regular insulin is a human insulin or pig insulin.

24. The method of claim 22, wherein the regular insulin is an insulin with an A chain having a sequence of amino acids set forth in SEQ ID NO:

103 and a B chain having a sequence of amino acids set forth in SEQ ID NO;

104 or an insulin with an A chain with a sequence of amino acids set forth as amino acid residue positions 88-108 of SEQ ID NO;

123 and a B chain with a sequence of amino acids set forth as amino acid residue positions 25-54 of SEQ ID NO;

123.

25. The method of claim 1, wherein the fast-acting insulin is an insulin analog.

26. The method of claim 25, wherein the fast-acting insulin is an insulin analog selected from among insulin lispro, insulin aspart or insulin glulisine.

27. The method of claim 25, wherein the insulin analog is selected from among an insulin having an A chain with a sequence of amino acids set forth in SEQ NOS:

103 and a B chain having a sequence of amino acids set forth in any of SEQ NOS;

147-149.

28. The method of claim 1, wherein:

the insulin composition comprises insulin in an amount that is between or about between 10 U/mL to 1000 U/mL;

or

the insulin composition comprises insulin in an amount that is between or about between 0.35 mg/mL to 35 mg/mL.

29. The method of claim 1, wherein the insulin in the composition is at least or is about at least or is 100 U/mL.

30. The method of claim 1, wherein the composition in step b) comprises a fast-acting insulin analog and a hyaluronan-degrading enzyme.

31. The method of claim 30, wherein:

the amount of fast-acting insulin analog in the composition is between or about between 10 U/mL to 1000 U/mL; and

the amount of a hyaluronan-degrading enzyme in the composition is functionally equivalent to between or about between 1 U/mL to 10,000 U/mL.

32. The method of claim 1, wherein the subject has diabetes.

33. The method of claim 32, wherein the diabetes is selected from among type 1 diabetes mellitus, type 2 diabetes mellitus and gestational diabetes.

34. A continuous subcutaneous insulin infusion (CSII) dosage regimen method for controlling blood glucose in a subject, comprising:

a) performing CSII to deliver a composition comprising a super fast-acting insulin composition to a subject in accord with a programmed basal rate and bolus dose of insulin; and

b) at least once during the course of treatment, increasing the amount of basal insulin and/or bolus insulin administered by at least 1% compared to the programmed basal rate and bolus dose of insulin administered in the absence of a hyaluronan-degrading enzyme thereby increasing insulin action.

35. The method of claim 34, wherein the basal insulin and/or bolus insulin administered are increased at least once per day.

36. The method of claim 34, wherein the super-fast acting insulin composition comprises:

a therapeutically effective amount of a fast-acting insulin analog for controlling blood glucose levels; and

an amount of a hyaluronan-degrading enzyme sufficient to render the composition a super fast-acting insulin composition.

37. The method of claim 36, wherein:

the amount of fast-acting insulin is from or from about 10 U/mL to 1000 U/mL; and

the sufficient amount of a hyaluronan-degrading enzyme to render the composition super fast-acting is functionally equivalent to 1 U/mL to 10,000 U/mL;

or

the amount of fast-acting insulin is from or from about 0.35 mg/mL to 35 mg/mL; and

the sufficient amount of a hyaluronan-degrading enzyme to render the composition super fast-acting is functionally equivalent to 8 ng/mL to 80 μ

g/mL.

38. The method of claim 34, wherein the subject has diabetes.

39. The method of claim 38, wherein the diabetes is selected from among type 1 diabetes mellitus, type 2 diabetes mellitus and gestational diabetes.